Phase 1b randomized, double-blind, placebo-controlled proof-of-mechanism trial of PLN-74809
Latest Information Update: 02 Mar 2022
Price :
$35 *
At a glance
- Drugs Bexotegrast (Primary)
- Indications Idiopathic pulmonary fibrosis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- Focus Adverse reactions
- Acronyms BAL
- 02 Mar 2022 New trial record
- 28 Feb 2022 Positive data from expanded phase published in the Pliant Therapeutics Media Release.